Eli Lilly and Co
LLY: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$396.00 | Bgqh | Dbhgsntmq |
Eli Lilly Looks Well Positioned to Drive Industry-Leading Growth, Aided by a Strong Pipeline
Business Strategy and Outlook
Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Following a very steep patent cliff in 2014, Lilly's growth prospects are improving as the company is launching several new blockbusters and patent losses are fading.